ABSTRACT
Influenza in long-term care facilities is an ever more challenging problem. Vaccination of residents and health care workers is the most important preventive measure. Although vaccine efficacy has been questioned, the preponderance of data favors vaccination. Antiviral resistance complicates postexposure chemoprophylaxis and treatment. Factors that limit the choice of antiviral agents in this patient population include limited vaccine supplies and impaired dexterity and confusion in long-term care residents.
Footnotes
↵* Dr. Mossad has disclosed that he is the site principal investigator for two multicenter studies sponsored by Roche Laboratories, the manufacturer of oseltamivir (Tamiflu).
- Copyright © 2009 The Cleveland Clinic Foundation. All Rights Reserved.